Management of AL amyloidosis in 2020
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …
Systemic amyloidosis from A (AA) to T (ATTR): a review
E Muchtar, A Dispenzieri, H Magen… - Journal of internal …, 2021 - Wiley Online Library
Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to
progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by …
progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by …
[HTML][HTML] Patisiran treatment in patients with transthyretin cardiac amyloidosis
MS Maurer, P Kale, M Fontana, JL Berk… - … England Journal of …, 2023 - Mass Medical Soc
Background Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with
accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive …
accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive …
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis
E Kastritis, G Palladini, MC Minnema… - … England Journal of …, 2021 - Mass Medical Soc
Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by
deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells …
deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells …
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
P Garcia-Pavia, C Rapezzi, Y Adler, M Arad… - European heart …, 2021 - academic.oup.com
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D …
P Garcia‐Pavia, C Rapezzi, Y Adler… - European journal of …, 2021 - Wiley Online Library
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy
M Fontana, SD Solomon, J Kachadourian… - … England Journal of …, 2024 - Mass Medical Soc
Background Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive,
often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on …
often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on …
Systemic immunoglobulin light chain amyloidosis
G Merlini, A Dispenzieri, V Sanchorawala… - Nature reviews Disease …, 2018 - nature.com
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by
the conversion of immunoglobulin light chains from their soluble functional states into highly …
the conversion of immunoglobulin light chains from their soluble functional states into highly …
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
The term monoclonal gammopathy of renal significance (MGRS) was introduced by the
International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The …
International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The …
Systemic amyloidosis
Tissue deposition of protein fibrils causes a group of rare diseases called systemic
amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach …
amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach …